Mangalam Drugs And Organics Limited
Incorporated in 1977, Mangalam Drugs& Organics Ltd manufactures Active Pharmaceutical Ingredients andIntermediates
What Mangalam files
- Others55
- Board Meeting20
- Important18
- Results6
- Pledging5
- Updates4
Mangalam Drugs and Organics reported the resignation of its Secretarial Auditor, M/s. Ragini Chokshi & Co. The auditor cited pre-occupancy with professional commitments as the reason for stepping down.
Mangalam Drugs & Organics' merger with Mangalam Laboratories and Shri B Pharma is set for final NCLT hearing. This key step moves the absorption scheme closer to fruition, pending final court sanction.
Mangalam Drugs' FY25 revenue fell to ₹318.73 Cr, yet PAT improved to ₹6.72 Cr from a loss. The company expanded its anti-malaria API portfolio with Pyronaridine and initiated in-house critical API manufacturing. A merger scheme was approved by the Board, and subsidiary property revaluation added ₹7.08 Cr surplus. No dividend...
Mangalam Drugs secured a repeat export order worth ~$18.2 Cr from a global client. Expected execution in 2-4 months, this order strengthens its market position and boosts revenue visibility.